Nydick M, Bustos J, Dale JH Jr, et al. Gynecomastia in adolescent boys. JAMA. 1961;178:449-454.
Nuttall FQ. Gynecomastia as a physical finding in normal men. J Clin Endocrinol Metab. 1979;48:338-340.
Niewoehner CB, Nuttall FQ. Gynecomastia in a hospitalized male population. Am J Med. 1984;77:633-637.
Braunstein GD. Gynecomastia. New Engl J Med. 1993;328:490-495.
Carlson HE. Gynecomastia. N Engl J Med. 1980;303:795-799.
Shozu M, Sebastian S, Takayama K, et al. Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene. N Engl J Med. 2003;348:1855-1865.
Thompson DF, Carter JR. Drug-induced gynecomastia. Pharmacotherapy. 1993;13:37-45.
Henley DV, Lipson N, Korach KS, et al. Prepubertal gynecomastia linked to lavender and tea tree oils. N Engl J Med. 2007;356:479-485.
Kunath F, Keck B, Antes G, et al. Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review. BMC Med. 2012;10:96.
Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536-2559.
Janes SE, Lengyel JA, Singh S, et al. Needle core biopsy for the assessment of unilateral breast masses in men. Breast. 2006;15:273-275.
Hines SL, Tan WW, Yasrebi M, et al. The role of mammography in male patients with breast symptoms. Mayo Clin Proc. 2007;82:297-300.
1. Niewoehner CB, Schorer AE. Gynaecomastia and breast cancer in men. BMJ. 2008;336:709-713.
2. Simon BE, Hoffman S, Kahn S. Classification and surgical correction of gynecomastia. Plast Reconstr Surg. 1973;51:48-52.
4. Nydick M, Bustos J, Dale JH Jr, et al. Gynecomastia in adolescent boys. JAMA. 1961;178:449-454.
5. Nuttall FQ. Gynecomastia as a physical finding in normal men. J Clin Endocrinol Metab. 1979;48:338-340.
6. Niewoehner CB, Nuttall FQ. Gynecomastia in a hospitalized male population. Am J Med. 1984;77:633-637.
7. Anderson JA, Gram JB. Male breast at autopsy. Acta Pathol Microbiol Immunol Scand. 1982;90:191-197.
8. Travison TG, Araujo AB, Kupelian V, et al. The relative contributions of aging, health and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab. 2007;92:549-555.
9. Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab. 2001;86:724-731.
10. Braunstein GD. Gynecomastia. New Engl J Med. 1993;328:490-495.
11. Carlson HE. Gynecomastia. N Engl J Med. 1980;303:795-799.
12. Deepinder F, Braunstein GD. Drug-induced gynecomastia: an evidence-based review. Expert Opin Drug Saf. 2012;11:779-795.
13. Shozu M, Sebastian S, Takayama K, et al. Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene. N Engl J Med. 2003;348:1855-1865.
14. Dobs A, Darkes MJ. Incidence and management of gynecomastia in men treated for prostate cancer. J Urol. 2005;174:1737-1742.
15. Schulman C, Pommerville P, Hofner K, et al. Long-term therapy with the dual 5alpha-reductase inhibitor dusteride is well tolerated in men with symptomatic benign prostatic hyperplasia. BJU Int. 2006;97:73-79.
16. Jensen RT, Collen MJ, Pandol SJ, et al. Cimetidine-induced impotence and breast changes in patients with gastric hypersecretory states. N Engl J Med. 1983;308:883-887.
17. Thompson DF, Carter JR. Drug-induced gynecomastia. Pharmacotherapy. 1993;13:37-45.
18. Finkelstein JS, McCully WF, MacLaughlin DT, et al. The mortician's mystery: gynecomastia and reversible hypogonadotropic hypogonadism in an embalmer. N Engl J Med. 1988;318:961-964.
19. Harrington JM, Stein GF, Rivera RO, et al. The occupational hazards of formulating oral contraceptives: a survey of plant employees. Arch Environ Health. 1978;33:12-15.
20. Henley DV, Lipson N, Korach KS, et al. Prepubertal gynecomastia linked to lavender and tea tree oils. N Engl J Med. 2007;356:479-485.
21. Durmaz E, Ozmert EN, Erkekoglu P, et al. Plasma phthalate levels in pubertal gynecomastia. Pediatrics. 2010;125:e122-e129.
22. Huffman DH, Kampmann JP, Hignite CE, et al. Gynecomastia induced in normal males by spironolactone. Clin Pharmacol Ther. 1978;24:465-473.
23. Bagatell CJ, Bremner WJ. Androgens in men: uses and abuses. N Engl J Med. 1996;334:707-714.
24. Perry PJ, Lund BC, Deninger MJ, et al. Anabolic steroid use in weight lifters and body builders: an internet survey of drug utilization. Clin J Sport Med. 2005;15:326-330.
25. Friedl KE, Yesalis CE. Self-treatment of gynecomastia in bodybuilders who use anabolic steroids. Physician Sportsmed. 1989;17:67-79.
26. Mira JA, Lozano F, Santos J, et al. Gynaecomastia in HIV-infected men on highly active antiretroviral therapy: association with efavirenz and didanosine treatment. Antivir Ther. 2004;9:511-517.
27. Dobs AS, Meikle AW, Arver S, et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999;84:3469-3478.
28. Boccardo F, Rubagotti A, Battaglia M, et al. Evaluation of tamoxifen and anastrazole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol. 2005;23:808-815.
29. Salzstein D, Sieber P, Morris T, et al. Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis. 2005;8:75-83.
30. Fradet Y, Egerdie B, Andersen M, et al. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. Eur Urol. 2007;52:106-114.
31. Viani GA, Bernardes da Silva LG, Stefano EJ. Prevention of gynecomastia and breast pain caused by androgen deprivation therapy in prostate cancer: tamoxifen or radiotherapy? Int J Radiat Oncol Biol Phys. 2012;83:e519-e524.
32. Kunath F, Keck B, Antes G, et al. Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review. BMC Med. 2012;10:96.
33. Lawrence SE, Faught KA, Vethamuthu J, et al. Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. J Pediatr. 2004;145:71-76.
34. Tyrrell CJ, Payne H, Tammela TL, et al. Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Int J Rad Oncol Biol Phys. 2004;60:476-483.
35. Perdona S, Autorino R, De Placido S, et al. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol. 2005;6:295-300.
36. Nuttall FQ, Warrier RS, Gannon MC. Gynecomastia and drugs: a critical evaluation of the literature. Eur J Clin Pharmacol. 2015;71:569-578.
37. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536-2559.
38. American College of Radiology. ACR appropriateness criteria: evaluation of the symptomatic male breast. 2014. http://www.acr.org (last accessed 25 October 2016).
39. Janes SE, Lengyel JA, Singh S, et al. Needle core biopsy for the assessment of unilateral breast masses in men. Breast. 2006;15:273-275.
40. Hines SL, Tan WW, Yasrebi M, et al. The role of mammography in male patients with breast symptoms. Mayo Clin Proc. 2007;82:297-300.
41. Tangerud Å, Potapenko I, Skjerven HK, et al. Radiologic evaluation of lumps in the male breast. Acta Radiol. 2016;57:809-814.
42. McDermott MT, Hofeldt FD, Kidd GS. Tamoxifen therapy for painful, idiopathic gynecomastia. South Med J. 1990;83:1283-1285.
43. Hanavadi S, Banerjee D, Monypenny IJ, et al. The role of tamoxifen in the management of gynaecomastia. Breast. 2006;15:276-280.
44. Jones DJ, Holt SD, Surtees P, et al. A comparison of danazol and placebo in the treatment of adult idiopathic gynaecomastia: results of a prospective study in 55 patients. Ann R Coll Surg Engl. 1990;72:296-298.
45. Ting AC, Chow LW, Leung YF. Comparison of tamoxifen with danazol in the management of idiopathic gynecomastia. Am Surg. 2000;66:38-40.
46. Buckle R. Danazol therapy in gynaecomastia; recent experience and indications for therapy. Postgrad Med J. 1979;55:71-78.
47. Babigian A, Silverman RT. Management of gynecomastia due to use of anabolic steroids in bodybuilders. Plast Reconstr Surg. 2001;107:240-242.
48. Fruhstorfer BH, Malata CM. A systematic approach to the surgical treatment of gynaecomastia. Br J Plast Surg. 2003;56:237-246.
49. Persichetti P, Berloco M, Casadei RM, et al. Gynecomastia and the complete circumareolar approach in the surgical management of skin redundancy. Plast Reconstr Surg. 2001;107:948-954.
50. Hodgson EL, Fruhstorfer BH, Malata CM. Ultrasonic liposuction in the treatment of gynecomastia. Plast Reconstr Surg. 2005;116:646-653.
51. Gabra HO, Morabito A, Bianchi A, et al. Gynaecomastia in the adolescent: a surgically relevant condition. Eur J Pediatr Surg. 2004;14:3-6.
52. Colombo-Benkmann M, Buse B, Stern J, et al. Indications for and results of surgical therapy for male gynecomastia. Am J Surg. 1999;178:60-63.
53. Trelles MA, Mordon SR, Bonanad E, et al. Laser-assisted lipolysis in the treatment of gynecomastia: a prospective study in 28 patients. Lasers Med Sci. 2013;28:375-382.
54. Messina M. Soybean isoflavone exposure does not have feminizing effects on men: a critical examination of the clinical evidence. Fertil Steril. 2010;93:2095-2104.
55. Bedognetti D, Rubagotti A, Conti G, et al. An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients. Eur Urol. 2010;57:238-245.
56. Serretta V, Altieri V, Morgia G, et al. A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia. Clin Genitourin Cancer. 2012;10:174-179.
57. Van Poppel H, Tyrrell CJ, Haustermans K, et al. Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer. Eur Urol. 2005;47:587-592.
58. Ozen H, Akyol F, Toktas G, et al. Is prophylactic breast radiotherapy necessary in all patients with prostate cancer and gynecomastia and/or breast pain? J Urol. 2010;184:519-524.
59. Tunio MA, Al-Asiri M, Al-Amro A, et al. Optimal prophylactic and definitive therapy for bicalutamide-induced gynecomastia: results of a meta-analysis. Curr Oncol. 2012;19:e280-e288.
60. Nuzzi LC, Cerrato FE, Erickson CR, et al. Psychosocial impact of adolescent gynecomastia: a prospective case-control study. Plast Reconstr Surg. 2013;131:890-896.
61. Lapid O, van Wingerden JJ, Perlemuter L. Tamoxifen therapy for the management of pubertal gynecomastia: a systematic review. J Pediatr Endocrinol Metab. 2013;26:803-807.
62. Eberle AJ, Sparrow JT, Keenan BS. Treatment of persistent pubertal gynecomastia with dihydrotestosterone heptanoate. J Pediatr. 1986;109:144-149.
63. Plourde PV, Kulin HE, Santner SJ. Clomiphene in the treatment of adolescent gynecomastia. Am J Dis Child. 1983;137:1080-1082.
64. Koshy JC, Goldberg JS, Wolfswinkel EM, et al. Breast cancer incidence in adolescent males undergoing subcutaneous mastectomy for gynecomastia: is pathologic examination justified? A retrospective and literature review. Plast Reconstr Surg. 2011;127:1-7.
65. Einav-Bachar R, Phillip M, Aurbach-Klipper Y, et al. Prepubertal gynaecomastia: aetiology, course and outcome. Clin Endocrinol. 2004;61:55-60.
使用此内容应接受我们的免责声明。
BMJ临床实践的持续改进离不开您的帮助和反馈。如果您发现任何功能问题和内容错误,或您对BMJ临床实践有任何疑问或建议,请您扫描右侧二维码并根据页面指导填写您的反馈和联系信息*。一旦您的建议在我们核实后被采纳,您将会收到一份小礼品。
如果您有紧急问题需要我们帮助,请您联系我们。
邮箱:bmjchina.support@bmj.com
电话:+86 10 64100686-612
*您的联系信息仅会用于我们与您确认反馈信息和礼品事宜。
BMJ临床实践官方反馈平台